For this purpose, we developed a scoring system (POLE Score) that considers PD-L1 expression, in both tumor and stromal cells, in terms of (i) overall PD-L1 expression (P) (ii) cellular origin of PD-L1 (O) (iii) PD-L1 expression in tumor-associated lymph follicles (L) and (iv) enumerated local PD-L1 distribution (E). The gene discussed is CD274; the disease is neoplasm.